InMed Pharmaceuticals Inc. Stock price

Equities

INM

CA4576376012

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.364 USD +4.96% Intraday chart for InMed Pharmaceuticals Inc. -1.17% -12.50%
Sales 2024 * 7.3M 5.39M Sales 2025 * 9.12M 6.74M Capitalization 2.98M 2.2M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 0.41 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.33 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 13
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.64%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on InMed Pharmaceuticals Inc.

1 day+4.96%
1 week-1.17%
Current month-12.29%
1 month-13.33%
3 months-6.19%
6 months-47.25%
Current year-12.50%
More quotes
1 week
0.33
Extreme 0.332
0.38
1 month
0.33
Extreme 0.3285
0.47
Current year
0.31
Extreme 0.31
0.47
1 year
0.29
Extreme 0.2913
2.08
3 years
0.29
Extreme 0.2913
99.75
5 years
0.29
Extreme 0.2913
370.43
10 years
0.29
Extreme 0.2913
1 608.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 16-06-15
Chief Operating Officer - 18-11-04
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 57 22-02-10
Chief Executive Officer 61 16-06-15
Chairman 61 16-09-11
More insiders
Date Price Change Volume
24-03-28 0.364 +4.96% 59,806
24-03-27 0.3468 +0.49% 62,624
24-03-26 0.3451 -4.14% 76,604
24-03-25 0.36 -5.21% 60,538
24-03-22 0.3798 +3.12% 64,220

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock InMed Pharmaceuticals Inc. - Nasdaq